Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 1/2008

01-12-2008 | Clinical Trial Report

A phase I study of gemcitabine plus palliative radiation therapy for advanced lung cancer

Authors: Brian Choi, H. Ian Robins, Joan Schiller, Minesh Mehta

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2008

Login to get access

Abstract

Purpose

To determine the maximum-tolerated dose (MTD) and antitumor activity of twice-weekly gemcitabine when combined with palliative-dose thoracic radiation therapy (RT) in patients with recurrent or progressive lung cancer.

Methods

Patients were enrolled in a dose-escalating study of gemcitabine with a starting dose level of 40 mg/m2 given as 30-minute infusions twice weekly concurrent with RT. The RT dose was 30 Gy in 10 fractions, 5 fractions per week.

Results

A total of 18 patients were enrolled on three dose levels: 40, 50, and 65 mg/m2. Four patients came off study early due to rapid progression of disease and therefore were not evaluated. The MTD of gemcitabine was found to be 50 mg/m2. Dose-limiting toxicities were grade-4 esophagitis in one patient and grade-4 neutropenia in another patient. Overall response included 1 partial response (PR). Local response included six PR, four minor response (MR), three stable disease (SD), and one progressive disease (PD).

Conclusion

The MTD of gemcitabine with concominant palliative thoracic radiation therapy is 50 mg/m2 twice weekly. The DLTs observed were grade-4 esophagitis and grade-4 myelotoxicity at 65 mg/m2.
Literature
1.
2.
Kramer GWPM, Wanders SL, Noordijk EM, et al (2005) Results of the dutch national study of the palliative effect of irradiation using two different treatment schemes for non-small-cell lung cancer. J Clin Oncol 23:2962PubMedCrossRef
3.
Furuse K, Fukuoka M, Kawahara M, et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692PubMed
4.
Curran WJ Jr, Scott CB, Langer CJ, et al (2003) Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III nsclc: RTOG 9410. Proc Am Soc Clin Oncol 22:621
5.
Fournel P, Robinet G, Thomas P, et al (2005) Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: groupe lyon-saint-etienne d’oncologie thoracique-groupe francais de pneumo-cancerologie NPC 95-01 study. J Clin Oncol 23:5910PubMedCrossRef
6.
Lawrence TS,William Blackstock A, McGinn C (2002) The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 13(1):13
7.
Pauwels B, Korst AEC, Lardon F, et al (2005) Combined modality therapy of gemcitabine and radiation. Oncologist 10:34PubMedCrossRef
8.
Joschko MA, Webster LK, Groves J, et al (1997) Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model. Radiat Oncol Investig 5:62PubMedCrossRef
9.
Cesario A, Margaritora S, Trodella L, et al (2002) Incidental surgical findings of a phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with unresectable non-small cell lung cancer. Lung Cancer 37(2):207PubMedCrossRef
10.
Trodella L, Granone P, Valente S, et al (2002) Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer. J Clin Oncol 20:804PubMedCrossRef
11.
van Putten JWG, Price A, van der Leest AHD, et al (2003) A phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. Clin Cancer Res 9:2472PubMed
12.
Abacioglu U, Yumuk P, Caglar H, et al (2005) Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer. BMC Cancer 5:71PubMedCrossRef
13.
Blackstock AW, Lesser G, Fletcher-Steede J, et al (2001) Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non–small-cell lung cancer. Int J Radiat Oncol Biol Phys 51:1281PubMed
14.
Shewach DS, Hahn TM, Chang E, et al (1994) Metabolism of 2’,2’-difluoro-2’-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 54:3218PubMed
15.
Lawrence T, Chang E, Hahn T, et al (1997) Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2’,2’-difluoro-2’-deoxycytidine (gemcitabine). Clin Cancer Res 3:777PubMed
16.
Scalliet P, Goor C, Galdermans D, et al (1998) Gemzar(R) (gemcitabine) with thoracic radiotherapy––a phase II pilot study in chemonaive patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 17:499a
17.
Vokes EE, Herndon JE II, Crawford J, et al (2002) Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and leukemia group B study 9431. J Clin Oncol 20:4191PubMedCrossRef
18.
Blackstock AW, Socinski MA, Gu L, et al (2005) Initial pulmonary toxicity evaluation of chemoradiotherapy (CRT) utilizing 74 gy 3-dimensional (3-D) thoracic radiation in stage III non-small cell lung cancer (NSCLC): a cancer and leukemia group B (CALGB) randomized phase II trial. J Clin Oncol (Meeting Abstracts) 23:7060
Metadata
Title
A phase I study of gemcitabine plus palliative radiation therapy for advanced lung cancer
Authors
Brian Choi
H. Ian Robins
Joan Schiller
Minesh Mehta
Publication date
01-12-2008
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2008
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-008-0708-8

Other articles of this Issue 1/2008

Cancer Chemotherapy and Pharmacology 1/2008 Go to the issue

Original Article

In vitro evaluation of dichloro-bis(pyrazole)palladium(II) and dichloro-bis(pyrazole)platinum(II) complexes as anticancer agents

Original Article

A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer

Original Article

Resveratrol analog trans 3,4,5,4′-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol

Original Article

Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model

Original Article

Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution

Original Article

A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits